Neurocrine Biosciences Inc. Share Price Today: Live Updates & Key Insights

Neurocrine Biosciences Inc. share price today is $127.68, up -1.56%. The stock opened at $129.81 against the previous close of $129.7, with an intraday high of $129.81 and low of $126.77.

Neurocrine Biosciences Inc. Share Price Chart

Neurocrine Biosciences Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Neurocrine Biosciences Inc. Share Price Performance

$127.68 -0.0156(-1.56%) NBIX at 23 Mar 2026 02:25 PM Drug Manufacturers - Specialty & Generic
Lowest Today 126.77
Highest Today 129.81
Today’s Open 129.81
Prev. Close 129.7
52 Week High 160.18
52 Week Low 84.23
Day’s Range: Low 126.77 High 129.81
52-Week Range: Low 84.23 High 160.18
1 day return -
1 Week return -1.75
1 month return -0.59
3 month return -13.5
6 month return -12.97
1 year return +10.35
3 year return +34.03
5 year return +38.36
10 year return -

Neurocrine Biosciences Inc. Institutional Holdings

BlackRock Inc 12.66

Vanguard Group Inc 9.67

JPMorgan Chase & Co 9.43

Dodge & Cox 5.49

State Street Corp 4.33

Dodge & Cox Stock I 3.95

AQR Capital Management LLC 3.26

iShares Core S&P Mid-Cap ETF 3.21

Vanguard Total Stock Mkt Idx Inv 3.12

T. Rowe Price Associates, Inc. 2.86

Vanguard Small Cap Index 2.25

Renaissance Technologies Corp 2.23

Geode Capital Management, LLC 2.05

Morgan Stanley - Brokerage Accounts 1.82

BB Biotech AG Ord 1.75

Wellington Management Company LLP 1.74

Bellevue Group AG 1.70

Vanguard Small Cap Growth Index Inv 1.25

Los Angeles Capital Management LLC 1.20

Deerfield Management Co 1.18

JPMorgan Growth Advantage A 1.18

NORGES BANK 1.14

Vanguard Institutional Extnd Mkt Idx Tr 1.07

JPM US Mid Cap Growth-Composite 1.07

JPMorgan Mid Cap Growth I 1.07

RTW INVESTMENTS, LLC 1.06

Two Sigma Investments LLC 0.98

BNP Paribas Investment Partners SA 0.94

Vanguard Windsor Investor Shares 0.93

Northern Trust Corp 0.92

Charles Schwab Investment Management Inc 0.85

JPM US Growth Advantage-MA 0.76

iShares Biotechnology ETF 0.72

State Street® SPDR® S&P MIDCAP 400® ETF 0.72

State Street® SPDR® S&P® Biotech ETF 0.62

First Trust NYSE Arca Biotech ETF 0.60

T. Rowe Price US Mid-Cap Value Equity 0.60

State St Russell Sm/Mid Cp® Indx SL Cl I 0.57

iShares Russell Mid-Cap Growth ETF 0.56

iShares S&P Mid-Cap 400 Growth ETF 0.55

Neurocrine Biosciences Inc. Market Status

Strong Buy: 15

Buy: 7

Hold: 3

Sell: 0

Strong Sell: 0

Neurocrine Biosciences Inc. Fundamentals

Market Cap 12814.41 M

PB Ratio 4.0015

PE Ratio 27.7565

Enterprise Value 11952.04 M

Total Assets 4631.50 M

Volume 2182008

Neurocrine Biosciences Inc. Company Financials

Annual Revenue FY25:2860500000 2860.5M, FY24:2355300000 2355.3M, FY23:1783900000 1783.9M, FY22:1488700000 1488.7M, FY21:1133500000 1133.5M

Annual Profit FY25:2808400000 2808.4M, FY24:2321300000 2321.3M, FY23:1745000000 1745.0M, FY22:1465500000 1465.5M, FY21:1119200000 1119.2M

Annual Net worth FY25:478600000 478.6M, FY24:341300000 341.3M, FY23:191000000 191.0M, FY22:154500000 154.5M, FY21:89600000 89.6M

Quarterly Revenue Q4/2025:805500000 805.5M, Q3/2025:794900000 794.9M, Q2/2025:687500000 687.5M, Q1/2025:572600000 572.6M, Q4/2024:627700000 627.7M

Quarterly Profit Q4/2025:787900000 787.9M, Q3/2025:780900000 780.9M, Q2/2025:676200000 676.2M, Q1/2025:563400000 563.4M, Q4/2024:618400000 618.4M

Quarterly Net worth Q4/2025:153700000 153.7M, Q3/2025:209500000 209.5M, Q2/2025:107500000 107.5M, Q1/2025:7900000 7.9M, Q4/2024:103100000 103.1M

About Neurocrine Biosciences Inc. & investment objective

Company Information Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Organisation Drug Manufacturers - Specialty & Generic

Employees 2000

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Kyle W. Gano Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Neurocrine Biosciences Inc. FAQs

What is the share price of Neurocrine Biosciences Inc. today?

The current share price of Neurocrine Biosciences Inc. is $127.68.

Can I buy Neurocrine Biosciences Inc. shares in India?

Yes, Indian investors can buy Neurocrine Biosciences Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Neurocrine Biosciences Inc. shares in India?

You can easily invest in Neurocrine Biosciences Inc. shares from India by:

Can I buy fractional shares of Neurocrine Biosciences Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Neurocrine Biosciences Inc.?

Neurocrine Biosciences Inc. has a market cap of $12814.41 M.

In which sector does Neurocrine Biosciences Inc. belong?

Neurocrine Biosciences Inc. operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in Neurocrine Biosciences Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Neurocrine Biosciences Inc.?

The PE ratio of Neurocrine Biosciences Inc. is 27.76 and the PB ratio is 4.00.